Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions

Human Gene Therapy

Volumn 11, Issue 12, 2000, Pages 1625-1635

  Mano, Toshiaki ^a   Luo, Zhengyu ^a   Suhara, Toshimitsu ^a   Smith, Roy C ^a   Esser, Sybille ^a   Walsh, Kenneth ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE;

ALANINE AMINOTRANSFERASE; BETA GALACTOSIDASE; DOXYCYCLINE; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; HYBRID PROTEIN; MEMBRANE PROTEIN; TNFSF6 PROTEIN, RAT; TRANSACTIVATOR PROTEIN;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; BLOOD; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CELL CULTURE; DBA MOUSE; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; HYPERPLASIA; INTIMA; MALE; METABOLISM; MOUSE; PATHOLOGY; RAT; REPORTER GENE; SPRAGUE DAWLEY RAT; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ALANINE TRANSAMINASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; CAROTID ARTERIES; CAROTID STENOSIS; CELLS, CULTURED; DOXYCYCLINE; ESCHERICHIA COLI; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HERPES SIMPLEX VIRUS PROTEIN VMW65; HUMANS; HYPERPLASIA; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATORS; TUNICA INTIMA;

EID: 0034632431     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050111287     Document Type: Article

References (51)

1. AMBAR, B.B., FREI, K., MALIPIERO, U., MORELLI, A.E., CASTRO, M.G., LOWENSTEIN, P.R., and FONTANA, A. (1999). Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum. Gene Ther. 10, 1641-1648.
2. ARAI, H., GORDON, D., NABEL, E.G., and NABEL, G.J. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U.S.A. 94, 13682-13867.
3. BELLGRAU, D., GOLD, D., SELAWRY, H., MOORE, J., FRANZUSOFF, A., and DUKE, R.C. (1995). A role of CD95 ligand in preventing graft rejection. Nature (London) 377, 630-632.
4. BEUTLER, B., and CERAMI, A. (1986). Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (London) 320, 584-588.
5. CORTI, O., SABATE, O., HORELLOU, P., COLIN, P., DUMAS, S., BUCHET, D., BUCCARON, M.H., and MALLET, J. (1999). A single adenovirus vector mediates doxycycline-con trolled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nature Biotechnol. 17, 349-354.
6. DAS, H., IMOTO, S., MURAYAMA, T., KAJIMOTO, K., SUGIMOTO, T., ISOBE, T., NAKAGAWA, T., NISHIMURA, R., and KOIZUMI, T. (1999). Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br. J. Haematol. 104, 795-800.
7. DUSSAILLANT, G.R., MINTZ, G.S., PICHARD, A.D., KENT, K.M., SALTER, L.F., POPMA, J.J., WONG, S.C., and LEON, M.B. (1995). Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J. Am. Coll. Cardiol. 26, 720-724.
8. GHERSA, P., GOBERT, R.P., SATTONNET-ROCHE, P., RICHARDS, C.A., MERLO PICH, E., and HOOFT VAN HUIJSDUIJNEN, R. (1998). Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther. 5, 1213-1220.
9. GOSSEN, M., and BUJARD, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547-5551.
10. GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., and BUJARD, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
11. GRAHAM, F.L., and PREVEC, L. (1992). Adenovirus-based expression vectors and recombinant vaccines. BioTechnology 20, 363-390.
12. GRAHAM, F.L., and VAN DER EB, A.J. (1973). A new technique for assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467.
13. GRIFFITH, T.S., BRUNNER, T., FLETCHER, S.M., GREEN, D.R., and FERGUSON, T.A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192.
14. HAHNE, M., RIMOLDI, D., SCHRÖTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P., BORNAND, T., FONTANA, A., LIENARD, D., CEROTTINI, J.-C., and TSCHOPP, J. (1996). Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274, 1363-1366.
15. HARDING, T.C., GEDDES, B.J., NOEL, J.D., MURPHY, D., and UNEY, J.B. (1997). Tetracycline-regulated transgene expression in hippocampal neurons following transfection with adenoviral vectors. J. Neurochem. 69, 2620-2623.
16. HARDING, T.C., GEDDES, B.J., MURPHY, D., KNIGHT, D., and UNEY, J.B. (1998). Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nature Biotechnol 16, 553-555. [See comments]
17. HASEGAWA, D., KOJIMA, S., TATSUMI, E., HAYAKAWA, A., KOSAKA, Y., NAKAMURA, H., SAKO, M., OSUGI, Y., NAGATA, S., and SANO, K. (1998). Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 91, 2793-2799.
18. HU, S.X., JI, W., ZHOU, Y., LOGOTHETIS, C., and XU, H.J. (1997). Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57, 3339-3343.
19. KANDA, Y., TANAKA, Y., SHIRAKAWA, K., YATOMI, T., NAKAMURA, N., KAMI, M., SAITO, T., IZUTSU, K., ASAI, T., YUJI, K., OGAWA, S., HONDA, H., MITANI, K., CHIBA, S., YAZAKI, Y., and HIRAI, H. (1998). Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 22, 751-754.
20. KATO, K., OHSHIMA, K., ISHIHARA, S., ANZAI, K., SUZUMIYA, J., and KIKUCHI, M. (1998). Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br. J. Haematol. 103, 1164-1166.
21. KEARNEY, M., PIECZEK, A., HALEY, L., LOSORDO, D.W., ANDRÉS, V., SCHAINFELD, R., ROSENFIELD, K., and ISNER, J.M. (1997). Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95, 1998-2002.
22. LARREGINA, A.T., MORELLI, A.E., DEWEY, R.A., CASTRO, M.G., FONTANA, A., and LOWENSTEIN, P.R. (1998). FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate El-deleted adenoviral vectors. Gene Ther. 5, 563-568.
23. LEE, S.W., TRAPNELL, B.C., RADE, J.J., VIRMANI, R., and DICHEK, D.A. (1993). In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ. Res. 73, 797-807.
24. LUO, Z., SATA, M., NGUYEN, T., KAPLAN, J.M., AKITA, G.Y., and WALSH, K. (1999). Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 99, 1776-1779.
25. MASSIE, B., COUTURE, F., LAMOUREUX, L., MOSSER, D.D., GUILBAULT, C., JOLICOEUR, P., BELANGER, F., and LANGELIER, Y. (1998). Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J. Virol. 72, 2289-2296.
26. MOLIN, M., SHOSHAN, M.C., OHMAN-FORSLUND, K., LINDER, S., and AKUSJARVI, G. (1998). Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J. Virol. 72, 8358-8361.
27. MURUVE, D.A., NICOLSON, A.G., MANFRO, R.C., STROM, T.B., SUKHATME, V.P., and LIBERMANN, T.A. (1997). Adenovirus mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo infected pancreatic islet allografts and isografts. Hum. Gene Ther. 8, 955-963.
28. NAGATA, S., and GOLSTEIN, P. (1995). The Fas death factor. Science 267, 1449-1456.
29. NIEHANS, G.A., BRUNNER, T., FRIZELLE, S.P., LISTON, J.C., SALERNO, C.T., KNAPP, D.J., GREEN, D.R., and KRATZKE, R.A. (1997). Human lung carcinomas express Fas ligand. Cancer Res. 57, 1007-1012.
30. NOBUYOSHI, M., KIMURA, T., OHISHI, H., HORIUCHI, H., NOSAKA, H., HAMASAKI, N., YOKOI, H., and KIM, K. (1991). Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients. J. Am. Coll. Cardiol. 17, 433-439.
31. NOZAWA, K., KAYAGAKI, N., TOKANO, Y., YAGITA, H., OKUMURA, K., and HASIMOTO, H. (1997). Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 40, 1126-1129. [See comments]
32. OGASAWARA, J., WATANABE-FUKUNAGA, R., ADACHI, M., MATSUZAWA, A., KASUGAI, T., KITAMURA, Y., ITOH, N., SUDA, T., and NAGATA, S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature (London) 364, 806-809. [Published erratum appears in Nature (London) 1993;365:568].
33. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London) 362, 801-809.
34. SAKAI, T., INOUE, A., KOH, C.S., and OSAME, M. (1999). Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Interferon Cytokine Res. 19, 999-1004.
35. SATA, M., and WALSH, K. (1998a). Endothelial cell apoptosis induced by oxidized LDL is associated with the downregulation of the cellular caspase inhibitor FLIP. J. Biol. Chem. 273, 33103-33106.
36. SATA, M., and WALSH, K. (1998b). Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J. Clin. Invest. 102, 1682-1689.
37. SATA, M., and WALSH, K. (1998c). TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nature Med. 4, 415-420.
38. SATA, M., PERLMAN, H., MURUVE, D.A., SILVER, M., IKEBE, M., LIBERMANN, T.A., OETTGEN, P., and WALSH, K. (1998). Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. U.S.A. 95, 1213-1217.
39. SATA, M., SUHARA, T., and WALSH, K. (2000). Vascular endothelial cells and smooth muscle cells differ in their expression of Fas and Fas ligand and in their sensitivity to Fas ligand-induced cell death: Implications for vascular disease and therapy. Arterioscler. Thromb. Vasc. Biol. 20, 309-316.
40. SCHNEIDER, P., HOLLER, N., BOOMER, J.L., HAHNE, M., FREI, K., FONTANA, A., and TSCHOPP, J. (1998). Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213.
41. SCHWARTZ, R.S., HOLMES, D.R., and TOPOL, E.J. (1992). The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20, 1284-1293.
42. SHINOURA, N., OHASHI, M., YOSHIDA, Y., ASAI, A., KIRINO, T., SAITO, I., and HAMADA, H. (1998a). Construction, propagation, and titer estimation of recombinant adenoviruses carrying proapoptotic genes. Hum. Gene Ther. 9, 2683-2689.
43. SHINOURA, N., YOSHIDA, Y., SADATA, A., HANADA, K.I., YAMAMOTO, S., KIRINO, T., ASAI, A., and HAMADA, H. (1998b). Apoptosis by retrovirus-and adenovirus-mediated gene transfer of Fas ligand to glioma cell: Implications for gene therapy. Hum. Gene Ther. 9, 1983-1993.
44. SUDA, T., HASHIMOTO, H., TANAKA, M., OCHI, T., and NAGATA, S. (1997). Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186, 2045-2050.
45. TANAKA, M., SUDA, T., HAZE, K., NAKAMURA, N., SATO, K., KIMURA, F., MOTOYOSHI, K., MIZUKI, M., TAGAWA, S., OHGA, S., HATAKE, K., DRUMMOND, A.H., and NAGATA, S. (1996). Fas ligand in human serum. Nature Med. 2, 317-322.
46. TANAKA, M., ITAI, T., ADACHI, M., and NAGATA, S. (1998). Downregulation of Fas ligand by shedding. Nature Med. 4, 31-36.
47. TOYOZAKI, T., HIROE, M., TANAKA, M., NAGATA, S., OHWADA, H., and MARUMO, F. (1998). Levels of soluble Fas ligand in myocarditis. Am. J. Cardiol. 82, 246-248.
48. YAMAGUCHI, S., YAMAOKA, M., OKUYAMA, M., NITOUBE, J., FUKUI, A., SHIRAKABE, M., SHIRAKAWA, K., NAKAMURA, N., and TOMOIKE, H. (1999). Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am. J. Cardiol. 83, 1500-1503, A8.
49. YOSHIDA, Y., and HAMADA, H. (1997). Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem. Biophys. Res. Commun. 230, 426-430.
50. ZHANG, H., YANG, Y., HORTON, J.L., SAMOILOVA, E.B., JUDGE, T.A., TURKA, L.A., WILSON, J.M., and CHEN, Y. (1997). Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100, 1951-1957.
51. ZHANG, H.G., LIU, D., HEIKE, Y., YANG, P., WANG, Z., WANG, X., CURIEL, D.T., ZHOU, T., and MOUNTZ, J.D. (1998). Induction of specific T-cell tolerance by adenovirus-transfected. Fas ligand-producing antigen presenting cells. Nature Biotechnol. 16, 1045-1049. [See comments]